477 related articles for article (PubMed ID: 29609659)
1. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
[TBL] [Abstract][Full Text] [Related]
2. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
3. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
4. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
6. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
[TBL] [Abstract][Full Text] [Related]
7. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.
Arora U; Tyagi P; Swaminathan S; Khanna N
J Nanobiotechnology; 2012 Jul; 10():30. PubMed ID: 22794664
[TBL] [Abstract][Full Text] [Related]
9. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
Uno N; Ross TM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
[TBL] [Abstract][Full Text] [Related]
10. Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody.
Shen WF; Galula JU; Liu JH; Liao MY; Huang CH; Wang YC; Wu HC; Liang JJ; Lin YL; Whitney MT; Chang GJ; Chen SR; Wu SR; Chao DY
Elife; 2018 Oct; 7():. PubMed ID: 30334522
[TBL] [Abstract][Full Text] [Related]
11. Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.
Young E; Carnahan RH; Andrade DV; Kose N; Nargi RS; Fritch EJ; Munt JE; Doyle MP; White L; Baric TJ; Stoops M; DeSilva A; Tse LV; Martinez DR; Zhu D; Metz S; Wong MP; Espinosa DA; Montoya M; Biering SB; Sukulpolvi-Petty S; Kuan G; Balmaseda A; Diamond MS; Harris E; Crowe JE; Baric RS
Cell Host Microbe; 2020 May; 27(5):710-724.e7. PubMed ID: 32407709
[TBL] [Abstract][Full Text] [Related]
12. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
[TBL] [Abstract][Full Text] [Related]
13. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
14. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
15. Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
VanBlargan LA; Milutinovic PS; Goo L; DeMaso CR; Durbin AP; Whitehead SS; Pierson TC; Dowd KA
J Virol; 2021 Nov; 95(23):e0095621. PubMed ID: 34549976
[TBL] [Abstract][Full Text] [Related]
16. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
Swanstrom JA; Nivarthi UK; Patel B; Delacruz MJ; Yount B; Widman DG; Durbin AP; Whitehead SS; De Silva AM; Baric RS
J Infect Dis; 2019 Jun; 220(2):219-227. PubMed ID: 30895307
[TBL] [Abstract][Full Text] [Related]
17. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
J Virol; 2021 May; 95(12):. PubMed ID: 33762420
[TBL] [Abstract][Full Text] [Related]
18. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.
Gallichotte EN; Baric TJ; Yount BL; Widman DG; Durbin A; Whitehead S; Baric RS; de Silva AM
PLoS Pathog; 2018 Feb; 14(2):e1006934. PubMed ID: 29481552
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.
Luo YY; Feng JJ; Zhou JM; Yu ZZ; Fang DY; Yan HJ; Zeng GC; Jiang LF
BMC Microbiol; 2013 Aug; 13():194. PubMed ID: 23987307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]